2024 Guidance:
Taking all of Astrana's recent growth initiatives and capital allocation strategy into account, the Company is updating its revenue, net income attributable to Astrana, and EPS - diluted guidance for 2024 while reiterating guidance for Adjusted EBITDA for the year ending December 31, 2024.
| ($ in millions, except per share amounts) | 2024 Guidance Range | |||||||
| Low | High | |||||||
| Total revenue | $ | 1,750 | $ | 1,850 | ||||
| Net income attributable to Astrana Health, Inc. | $ | 54 | $ | 66 | ||||
| Adjusted EBITDA | $ | 165 | $ | 185 | ||||
| EPS – diluted | $ | 1.12 | $ | 1.36 | ||||
See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.
